ロード中...
Population Pharmacokinetics and Exposure‐Response Analyses for CPX‐351 in Patients With Hematologic Malignancies
CPX‐351, a dual‐drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved in the United States for adults with newly diagnosed therapy‐related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia‐related changes. Population pharmacokinetics analy...
保存先:
| 出版年: | J Clin Pharmacol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6590377/ https://ncbi.nlm.nih.gov/pubmed/30566230 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1366 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|